(Alliance News) - Abingdon Health PLC shares were up on Monday, after it said it has launched Salistick, the first-ever saliva pregnancy test, in the UK and Ireland.
Shares in the lateral flow contract development and manufacturing company were up 10% to 16.20 pence each in London on Monday morning.
Abigdon is the exclusive distributor of Salistick in the UK and Ireland on behalf of Salignostics Ltd, an Israeli developer of innovative saliva-based diagnostics tests.
As well as providing distribution support, Abingdon said it has been providing Salignostics with contract development services in scaling-up the Salistick product for manufacture and will continue to provide Salignostics with contract manufacturing services going forward.
The company said the test will launch across 400 Superdrug stores and online on Superdrug.com. It will also launch the test on its own direct-to-consumer e-commerce channel, co-branded Abingdon Simply Test.
Abingdon added that it is estimated that 12.5 million pregnancy tests were performed in the UK in 2022. The global pregnancy test kits market was valued at USD1.70 billion in 2022 and is expected to reach USD 2.28 billion by 2028, it noted.
Chief Executive Officer Chris Yates said: "This novel technology provides women with an enhanced user-experience; offering the ability to test anywhere, anytime, and for the experience to be shared with a partner and other loved ones. We are pleased to have supported our partner Salignostics Ltd through the development process into manufacturing and now commercial launch, and we look forward to deepening our collaboration as we move forward."
By Sophie Rose, Alliance News reporter
Comments and questions to newsroom@alliancenews.com
Copyright 2023 Alliance News Ltd. All Rights Reserved.
Abingdon Healt. (ABDX)